Test batch of Sputnik V made in Mexico

5 July 2021
vaccine_sputnik_big

The Russian Direct Investment Fund (RDIF) and Laboratorios de Biológicos y Reactivos de México (BIRMEX) have announced the production of a test batch of the Russian Sputnik V vaccine against coronavirus.

Mexico has become the first North American country both to register Sputnik V and to launch local production of the vaccine, which will be used in the country’s national vaccination program.

The Mexican production of Sputnik V, a two-shot human adenovirus vaccine priced at less than $10, which can be stored in a conventional refrigerator, was agreed by the RDIF, Russia’s sovereign wealth fund, and BIRMEX.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical